View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 20, 2011

NICE Rejects Eisai Breast Cancer Drug

A UK health board has rejected Eisai's Halaven (eribulin) for the treatment of advanced metastatic breast cancer. In a draft guidance issued for public consultation, the National Institute for Health and Clinical Excellence (NICE) said that although the drug could potentially help patie

By cms admin

A UK health board has rejected Eisai’s Halaven (eribulin) for the treatment of advanced metastatic breast cancer.

In a draft guidance issued for public consultation, the National Institute for Health and Clinical Excellence (NICE) said that although the drug could potentially help patients live a little longer, it also caused more negative side effects than other treatments.

NICE chief executive Andrew Dillon said: “The majority of the evidence on the effectiveness of eribulin submitted by the manufacturer was based on one study that compared eribulin to a ‘treatment of physician’s choice’.

“The manufacturer and other stakeholders now have an opportunity to comment on the preliminary recommendations which are available for public consultation. Comments received during this consultation will be fully considered by the Committee and following this meeting the next draft guidance will be issued.”

Eisai has agreed a patient access scheme with the Department of Health which makes eribulin available at a discounted price.

The estimated cost for each quality-adjusted year of life gained through eribulin, compared with the ‘treatment of physician’s choice’, is thought to be in excess of £68,600.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology